Advanced search
Publication Cover
Leukemia & Lymphoma Volume 49, 2008 - Issue 3
Submit an article Journal homepage
420
Views
163
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

Paul Richardson Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USACorrespondence[email protected]
,
Constantine Mitsiades Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
,
Kathleen Colson Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
,
Eileen Reilly Hackensack University Medical Center, Hackensack, NJ, USA
,
Laura McBride Hackensack University Medical Center, Hackensack, NJ, USA
,
Judy Chiao Merck Research Laboratories, Upper Gwynedd, PA, USA
,
Linda Sun Merck Research Laboratories, Upper Gwynedd, PA, USA
,
Justin Ricker Merck Research Laboratories, Upper Gwynedd, PA, USA
,
Syed Rizvi Merck Research Laboratories, Upper Gwynedd, PA, USA
,
Carol Oerth Merck Research Laboratories, Upper Gwynedd, PA, USA
,
Barbara Atkins Merck Research Laboratories, Upper Gwynedd, PA, USA
,
Ivy Fearen Merck Research Laboratories, Upper Gwynedd, PA, USA
,
Kenneth Anderson Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
&
David Siegel Hackensack University Medical Center, Hackensack, NJ, USA
 show all
Pages 502-507 | Received 13 Aug 2007, Accepted 19 Nov 2007, Published online: 01 Jul 2009

Citations (163)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (22)

Beiwen Ni & Jian Hou. (2022) Promising therapeutic approaches for relapsed/refractory multiple myeloma. Hematology 27:1, pages 343-352.
Read now
Guldane Cengiz Seval & Meral Beksac. (2019) A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma. Expert Opinion on Drug Safety 18:7, pages 563-571.
Read now
Douglas W. Sborov, Alessandro Canella, Erinn M. Hade, Xiaokui Mo, Soun Khountham, Jiang Wang, Wenjun Ni, Ming Poi, Christopher Coss, Zhongfa Liu, Mitch A. Phelps, Amir Mortazavi, Leslie Andritsos, Robert A. Baiocchi, Beth A. Christian, Don M. Benson, Joseph Flynn, Pierluigi Porcu, John C. Byrd, Flavia Pichiorri & Craig C. Hofmeister. (2017) A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Leukemia & Lymphoma 58:10, pages 2310-2318.
Read now
Jacob P. Laubach, Jesus F. San-Miguel, Vania Hungria, Jian Hou, Philippe Moreau, Sagar Lonial, Jae Hoon Lee, Hermann Einsele, Melissa Alsina & Paul G. Richardson. (2017) Deacetylase inhibitors: an advance in myeloma therapy?. Expert Review of Hematology 10:3, pages 229-237.
Read now
Nidhi Tandon, Vijay Ramakrishnan & Shaji K Kumar. (2016) Clinical use and applications of histone deacetylase inhibitors in multiple myeloma. Clinical Pharmacology: Advances and Applications 8, pages 35-44.
Read now
Paul G Richardson, R Donald Harvey, Jacob P Laubach, Philippe Moreau, Sagar Lonial & Jesús F San-Miguel. (2016) Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. Expert Review of Clinical Pharmacology 9:1, pages 35-48.
Read now
Emmanuelle Le Ray, Sundar Jagannath & Antonio Palumbo. (2016) Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma. Expert Review of Hematology 9:1, pages 91-105.
Read now
Annemiek Broijl & Pieter Sonneveld. (2015) An update in treatment options for multiple myeloma in nontransplant eligible patients. Expert Opinion on Pharmacotherapy 16:13, pages 1945-1957.
Read now
Jacob P Laubach, Peter M Voorhees, Hani Hassoun, Andrzej Jakubowiak, Sagar Lonial & Paul G Richardson. (2014) Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Review of Hematology 7:1, pages 97-111.
Read now
Enrique M Ocio, Constantine S Mitsiades, Robert Z Orlowski & Kenneth C Anderson. (2014) Future agents and treatment directions in multiple myeloma. Expert Review of Hematology 7:1, pages 127-141.
Read now
Roman Hajek, David Siegel, Robert Z. Orlowski, Heinz Ludwig, Antonio Palumbo & Meletios Dimopoulos. (2014) The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma. Leukemia & Lymphoma 55:1, pages 11-18.
Read now
Amit Khot, Michael Dickinson & H Miles Prince. (2013) Panobinostat in lymphoid and myeloid malignancies. Expert Opinion on Investigational Drugs 22:9, pages 1211-1223.
Read now
Sonia Vallet & Klaus Podar. (2013) New insights, recent advances, and current challenges in the biological treatment of multiple myeloma. Expert Opinion on Biological Therapy 13:sup1, pages S35-S53.
Read now
Akinori Sato. (2012) Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects. OncoTargets and Therapy 5, pages 67-76.
Read now
Jeffrey L. Wolf, David Siegel, Hartmut Goldschmidt, Katharine Hazell, Priscille M. Bourquelot, Bourras R. Bengoudifa, Jeffrey Matous, Ravi Vij, Margarida de Magalhaes-Silverman, Rafat Abonour, Kenneth C. Anderson & Sagar Lonial. (2012) Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leukemia & Lymphoma 53:9, pages 1820-1823.
Read now
H. Miles Prince. (2012) Pioneering studies of histone deacetylase inhibitors in myeloma: signals of activity set the stage for combination therapy trials. Leukemia & Lymphoma 53:9, pages 1658-1659.
Read now
Paola Neri, Nizar J Bahlis & Sagar Lonial. (2012) Panobinostat for the treatment of multiple myeloma. Expert Opinion on Investigational Drugs 21:5, pages 733-747.
Read now
Erin M Bertino & Gregory A Otterson. (2011) Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opinion on Investigational Drugs 20:8, pages 1151-1158.
Read now
Peter Kovacic & Corey L. Edwards. (2011) Hydroxamic acids (therapeutics and mechanism): chemistry, acyl nitroso, nitroxyl, reactive oxygen species, and cell signaling. Journal of Receptors and Signal Transduction 31:1, pages 10-19.
Read now
Thomas Prebet & Norbert Vey. (2011) Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. Expert Opinion on Investigational Drugs 20:2, pages 287-295.
Read now
Jacob P Laubach, Constantine S Mitsiades, Teru Hideshima, Robert Schlossman, Dharminder Chauhan, Nikhil Munshi, Irene Ghobrial, Nicole Carreau, Kenneth C Anderson & Paul G Richardson. (2009) Bortezomib in the management of multiple myeloma. Cancer Management and Research 1, pages 107-117.
Read now
H. Miles Prince, Mark Bishton & Simon Harrison. (2008) The potential of histone deacetylase inhibitors for the treatment of multiple myeloma. Leukemia & Lymphoma 49:3, pages 385-387.
Read now

Articles from other publishers (141)

Bingxin Zhang, Quanqiang Wang, Zhili Lin, Ziwei Zheng, Shujuan Zhou, Tianyu Zhang, Dong Zheng, Zixing Chen, Sisi Zheng, Yu Zhang, Xuanru Lin, Rujiao Dong, Jingjing Chen, Honglan Qian, Xudong Hu, Yan Zhuang, Qianying Zhang, Zhouxiang Jin, Songfu Jiang & Yongyong Ma. (2023) A novel glycolysis-related gene signature for predicting the prognosis of multiple myeloma. Frontiers in Cell and Developmental Biology 11.
Crossref
Phuong Hong Nguyen, Bui Thi Buu Hue, Minh Quan Pham, Tran Phuong Hoa, Quang De Tran, Hosun Jung, Le Trong Hieu, Nguyen Cuong Quoc, Hong Vinh Quang, Nguyen Phu Quy, Hye Jin Yoo & Su-Geun Yang. (2023) Novel histone deacetylase 6 inhibitors using benzimidazole as caps for cancer treatment. New Journal of Chemistry 47:16, pages 7622-7631.
Crossref
Takeshi Harada, Hiroto Ohguchi, Asuka Oda, Michiyasu Nakao, Jumpei Teramachi, Masahiro Hiasa, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Tomoko Maruhashi, Mamiko Takahashi, Shiro Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki, Shigeki Sano, Teru Hideshima & Masahiro Abe. (2023) Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase. Blood Advances 7:6, pages 1019-1032.
Crossref
Darren Pan, Tarek H. Mouhieddine, Ranjan Upadhyay, Nicole Casasanta, Angela Lee, Nicole Zubizarreta, Erin Moshier & Joshua Richter. (2023) Outcomes with panobinostat in heavily pretreated multiple myeloma patients. Seminars in Oncology 50:1-2, pages 40-48.
Crossref
Yu-bo Zhou, Yang-ming Zhang, Hong-hui Huang, Li-jing Shen, Xiao-feng Han, Xiao-bei Hu, Song-da Yu, An-hui Gao, Li Sheng, Ming-bo Su, Xiao-li Wei, Yue Zhang, Yi-fan Zhang, Zhi-wei Gao, Xiao-yan Chen, Fa-jun Nan, Jia Li & Jian Hou. (2021) Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma. Acta Pharmacologica Sinica 43:4, pages 1091-1099.
Crossref
Amanda E. Crunk, Aneta Przepiorski & Neil A. Hukriede. 2022. Regenerative Nephrology. Regenerative Nephrology 451 464 .
Tao Liang, Junxin Xue, Zefu Yao, Yang Ye, Xinying Yang, Xuben Hou & Hao Fang. (2021) Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors. European Journal of Medicinal Chemistry 221, pages 113526.
Crossref
Manasa Gangadhar Shetty, Padmini Pai, Renita Esther Deaver, Kapaettu Satyamoorthy & Kampa Sundara Babitha. (2021) Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy. Pharmacological Research 170, pages 105695.
Crossref
Linda Anna Michelle Kulka, Pia-Victoria Fangmann, Diana Panfilova & Heidi Olzscha. (2020) Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease. Frontiers in Cell and Developmental Biology 8.
Crossref
Leona A. Holmberg, Damian Green, Edward Libby & P.S. Becker. (2020) Bortezomib and Vorinostat Therapy as Maintenance Therapy after Autologous Transplant for Multiple Myeloma. Acta Haematologica 143:2, pages 146-154.
Crossref
Nidhi Sharma, David T. Chen, Qiuhong Zhao, Nita Y. Williams, Ashley Rosko, Don M. Benson, Maria Chaudhry, Naresh Bumma, Abdullah Khan, Srinivas Devarakonda, Craig C. Hofmeister, Douglas Sborov & Yvonne A. Efebera. (2020) Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up. Biology of Blood and Marrow Transplantation 26:1, pages 44-49.
Crossref
Eduardo Izquierdo-Torres, Andrés Hernández-Oliveras, Iván Meneses-Morales, Gabriela Rodríguez, Gabriela Fuentes-García & Ángel Zarain-Herzberg. (2019) Resveratrol up-regulates ATP2A3 gene expression in breast cancer cell lines through epigenetic mechanisms. The International Journal of Biochemistry & Cell Biology 113, pages 37-47.
Crossref
Faiz Anwer, Kevin Mathew Gee, Ahmad Iftikhar, Mirza Baig, Atlantis Dawn Russ, Sabina Saeed, Muhammad Abu Zar, Faryal Razzaq, Jennifer Carew, Steffan Nawrocki, Hussam Al-Kateb, Nadia Nunes Cavalcante Parr, Ali McBride, Jason Valent & Christy Samaras. (2019) Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 19:7, pages 397-405.
Crossref
Liam Lawlor & Xuebin B. Yang. (2019) Harnessing the HDAC–histone deacetylase enzymes, inhibitors and how these can be utilised in tissue engineering. International Journal of Oral Science 11:2.
Crossref
Konstantinos Dimopoulos & Kirsten Grønbæk. (2019) Epigenetic therapy in hematological cancers. APMIS 127:5, pages 316-328.
Crossref
Hyungwoo Cho, Dok Hyun Yoon, Kyu-pyo Kim, Kyun-Seop Bae, Won Seog Kim, Hyeon-Seok Eom, Jin Seok Kim, Jung Yong Hong, Seok Jin Kim, Hyewon Lee, Soo-Jeong Kim & Cheolwon Suh. (2018) Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy. Investigational New Drugs 36:5, pages 877-885.
Crossref
Hanley N. Abramson. (2018) The Multiple Myeloma Drug Pipeline—2018: A Review of Small Molecules and Their Therapeutic Targets. Clinical Lymphoma Myeloma and Leukemia 18:9, pages 611-627.
Crossref
Hiroto Ohguchi, Teru Hideshima & Kenneth C. Anderson. (2018) The biological significance of histone modifiers in multiple myeloma: clinical applications. Blood Cancer Journal 8:9.
Crossref
Björn Tampe & Michael Zeisberg. (2018) Chromatin dynamics at the core of kidney fibrosis. Matrix Biology 68-69, pages 194-229.
Crossref
Ruosi Yao, Danyang Han, Xiaoyang Sun, Yu Xie, Qingyun Wu, Chunling Fu, Yao Yao, Hujun Li, Zhenyu Li & Kailin Xu. (2018) Scriptaid inhibits cell survival, cell cycle, and promotes apoptosis in multiple myeloma via epigenetic regulation of p21. Experimental Hematology 60, pages 63-72.
Crossref
Amila Suraweera, Kenneth J. O’Byrne & Derek J. Richard. (2018) Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi. Frontiers in Oncology 8.
Crossref
Nasrin Rastgoo, Jahangir Abdi, Jian Hou & Hong Chang. (2017) Role of epigenetics-microRNA axis in drug resistance of multiple myeloma. Journal of Hematology & Oncology 10:1.
Crossref
J Yu, H Wu, Z Lin, K Su, J Zhang, F Sun, X Wang, C Wen, H Cao & L Hu. (2017) Metabolic changes in rat serum after administration of suberoylanilide hydroxamic acid and discriminated by SVM. Human & Experimental Toxicology 36:12, pages 1286-1294.
Crossref
T Harada, H Ohguchi, Y Grondin, S Kikuchi, M Sagawa, Y-T Tai, R Mazitschek, T Hideshima & K C Anderson. (2017) HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications. Leukemia 31:12, pages 2670-2677.
Crossref
Alessandra Larocca, Roberto Mina, Francesca Gay, Sara Bringhen & Mario Boccadoro. (2017) Emerging drugs and combinations to treat multiple myeloma. Oncotarget 8:36, pages 60656-60672.
Crossref
Peter M. Voorhees, Cristina Gasparetto, Dominic T. Moore, Diane Winans, Robert Z. Orlowski & David D. Hurd. (2017) Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 17:7, pages 424-432.
Crossref
Saurabh Chhabra. (2017) Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics. Pharmaceuticals 10:4, pages 40.
Crossref
S Sengsayadeth, F Malard, B N Savani, L Garderet & M Mohty. (2017) Posttransplant maintenance therapy in multiple myeloma: the changing landscape. Blood Cancer Journal 7:3, pages e545-e545.
Crossref
Dharshan Sivaraj, Michael M Green & Cristina Gasparetto. (2017) Panobinostat for the management of multiple myeloma. Future Oncology 13:6, pages 477-488.
Crossref
Larysa Sanchez, David H. Vesole, Joshua R. Richter, Noa Biran, Elizabeth Bilotti, Laura McBride, Palka Anand, Kristin Ivanovski & David S. Siegel. (2017) A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens. British Journal of Haematology 176:3, pages 440-447.
Crossref
Andrew J Yee, William I Bensinger, Jeffrey G Supko, Peter M Voorhees, Jesus G Berdeja, Paul G Richardson, Edward N Libby, Ellen E Wallace, Nicole E Birrer, Jill N Burke, David L Tamang, Min Yang, Simon S Jones, Catherine A Wheeler, Robert J Markelewicz & Noopur S Raje. (2016) Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. The Lancet Oncology 17:11, pages 1569-1578.
Crossref
Takeshi Harada, Teru Hideshima & Kenneth C. Anderson. (2016) Histone deacetylase inhibitors in multiple myeloma: from bench to bedside. International Journal of Hematology 104:3, pages 300-309.
Crossref
Andrew Stiff, Enrico Caserta, Douglas W. Sborov, Gerard J. Nuovo, Xiaokui Mo, Sarah Y. Schlotter, Alessandro Canella, Emily Smith, Joseph Badway, Matthew Old, Alena Cristina Jaime-Ramirez, Pearlly Yan, Don M. Benson, John C. Byrd, Robert Baiocchi, Balveen Kaur, Craig C. Hofmeister & Flavia Pichiorri. (2016) Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma. Molecular Cancer Therapeutics 15:5, pages 830-841.
Crossref
Hans C. Lee, Tomer M. Mark & Jatin J. Shah. (2016) Practical Approaches to the Management of Dual Refractory Multiple Myeloma. Current Hematologic Malignancy Reports 11:2, pages 148-155.
Crossref
Madeleine Duvic & Meletios Dimopoulos. (2016) The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies. Cancer Treatment Reviews 43, pages 58-66.
Crossref
Sarah L. Greig. (2016) Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma. Targeted Oncology 11:1, pages 107-114.
Crossref
Heather Fairfield, Carolyne Falank, Lindsey Avery & Michaela R. Reagan. (2016) Multiple myeloma in the marrow: pathogenesis and treatments. Annals of the New York Academy of Sciences 1364:1, pages 32-51.
Crossref
Yoshiaki Ogawa, Michinori Ogura, Kensei Tobinai, Kiyoshi Ando, Tatsuya Suzuki, Takashi Watanabe, Ken Ohmachi, Toshiki Uchida, Mary E. Hanson, Yoshinobu Tanaka, Yasuhiro Koh, Takashi Shimamoto & Tomomitsu Hotta. (2015) A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma. International Journal of Hematology 103:1, pages 25-33.
Crossref
Paola Neri, Nizar J. Bahlis, Claudia Paba-Prada & Paul Richardson. 2016. Plasma Cell Dyscrasias. Plasma Cell Dyscrasias 169 194 .
Salma Afifi, Angela Michael, Mahshid Azimi, Mabel Rodriguez, Nikoletta Lendvai & Ola Landgren. (2015) Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 35:12, pages 1173-1188.
Crossref
Anna Wawruszak, Jarogniew J. Luszczki, Aneta Grabarska, Ewelina Gumbarewicz, Magdalena Dmoszynska-Graniczka, Krzysztof Polberg & Andrzej Stepulak. (2015) Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines – An Isobolographic Analysis. PLOS ONE 10:11, pages e0143013.
Crossref
Alireza Roostaee, Amel Guezguez, Marco Beauséjour, Aline Simoneau, Pierre H. Vachon, Emile Levy & Jean‐François Beaulieu. (2015) Histone Deacetylase Inhibition Impairs Normal Intestinal Cell Proliferation and Promotes Specific Gene Expression. Journal of Cellular Biochemistry 116:11, pages 2695-2708.
Crossref
Alessandro Canella, Hector Cordero Nieves, Douglas W. Sborov, Luciano Cascione, Hanna S. Radomska, Emily Smith, Andrew Stiff, Jessica Consiglio, Enrico Caserta, Lara Rizzotto, Nicola Zanesi, Volinia Stefano, Balveen Kaur, Xiaokui Mo, John C. Byrd, Yvonne A. Efebera, Craig C. Hofmeister & Flavia Pichiorri. (2015) HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. Oncotarget 6:31, pages 31134-31150.
Crossref
Douglas W. Sborov, Don M. Benson, Nita Williams, Ying Huang, Mindy A. Bowers, Kristina Humphries, Yvonne Efebera, Steven Devine & Craig C. Hofmeister. (2015) Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma. British Journal of Haematology 171:1, pages 74-83.
Crossref
Tao Yan-Fang, Li Zhi-Heng, Xu Li-Xiao, Fang Fang, Lu Jun, Li Gang, Cao Lan, Wang Na-Na, Du Xiao-Juan, Sun Li-Chao, Zhao Wen-Li, Xiao Pei-Fang, Zhao He, Su Guang-Hao, Li Yan-Hong, Li Yi-Ping, Xu Yun-Yun, Zhou Hui-Ting, Wu Yi, Jin Mei-Fang, Liu Lin, Ni Jian, Hu Shao-Yan, Zhu Xue-Ming, Feng Xing, Wang Jian & Pan Jian. (2015) Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells. PLOS ONE 10:7, pages e0126566.
Crossref
Emma M. Smith, Lei Zhang, Brian A. Walker, Emma L. Davenport, Lauren I. Aronson, David Krige, Leon Hooftman, Alan H. Drummond, Gareth J. Morgan & Faith E. Davies. (2013) The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway. Oncotarget 6:19, pages 17314-17327.
Crossref
XIAONING WANG & MEI ZHANG. (2015) Synergistic effects of valproic acid and arsenic trioxide on RPMI8226 cells in vitro and the possible underlying mechanisms. Molecular Medicine Reports 12:1, pages 1449-1456.
Crossref
Leila Haery, Ryan C. Thompson & Thomas D. Gilmore. (2015) Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy. Genes & Cancer 6:5-6, pages 184-213.
Crossref
Ken Maes, Eva De Smedt, Alboukadel Kassambara, Dirk Hose, Anja Seckinger, Els Van Valckenborgh, Eline Menu, Bernard Klein, Karin Vanderkerken, Jérôme Moreaux & Elke De Bruyne. (2014) In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma . Oncotarget 6:5, pages 3319-3334.
Crossref
Vijay Ramakrishnan, Teresa Kimlinger, Michael Timm, Jessica Haug, S. Vincent Rajkumar & Shaji Kumar. (2014) Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001. Leukemia Research 38:11, pages 1358-1366.
Crossref
K. Martin Kortuem, Kaitlyn Zidich, Steven R. Schuster, Meaghan L. Khan, Victor H. Jimenez-Zepeda, Joseph R. Mikhael, Rafael Fonseca & A. Keith Stewart. (2014) Activity of 129 Single-Agent Drugs in 228 Phase I and II Clinical Trials in Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 14:4, pages 284-290.e5.
Crossref
Charlotte Pawlyn, Martin F Kaiser, Faith E Davies & Gareth J Morgan. (2014) Current and potential epigenetic targets in multiple myeloma. Epigenomics 6:2, pages 215-228.
Crossref
E M Ocio, P G Richardson, S V Rajkumar, A Palumbo, M V Mateos, R Orlowski, S Kumar, S Usmani, D Roodman, R Niesvizky, H Einsele, K C Anderson, M A Dimopoulos, H Avet-Loiseau, U-H Mellqvist, I Turesson, G Merlini, R Schots, P McCarthy, L Bergsagel, C S Chim, J J Lahuerta, J Shah, A Reiman, J Mikhael, S Zweegman, S Lonial, R Comenzo, W J Chng, P Moreau, P Sonneveld, H Ludwig, B G M Durie & J F S Miguel. (2013) New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 28:3, pages 525-542.
Crossref
D S Siegel, P Richardson, M Dimopoulos, P Moreau, C Mitsiades, D Weber, J Houp, C Gause, S Vuocolo, J Eid, T Graef & K C Anderson. (2014) Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood Cancer Journal 4:2, pages e182-e182.
Crossref
Shaji Kumar & Arleigh McCurdy. 2014. Multiple Myeloma. Multiple Myeloma 131 140 .
Matthew J. Streetly, Jacob Laubach, Paul Richardson & Stephen A. Schey. 2013. Myeloma. Myeloma 144 166 .
Song Xu, Kim De Veirman, Karin Vanderkerken & Ivan Van Riet. (2013) Vorinostat-induced bone loss might be related to drug toxicity. Bone 57:2, pages 384-385.
Crossref
Giuseppe Giaccone & Jean-Charles SoriaAlexandra Zimmer, Arup Chakraborty, Robert Robey & Susan Bates. 2013. Targeted Therapies in Oncology, Second Edition. Targeted Therapies in Oncology, Second Edition 367 400 .
Robert Z. Orlowski. (2013) Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials. Seminars in Oncology 40:5, pages 634-651.
Crossref
Meletios Dimopoulos, David S Siegel, Sagar Lonial, Junyuan Qi, Roman Hajek, Thierry Facon, Laura Rosinol, Catherine Williams, Hilary Blacklock, Hartmut Goldschmidt, Vania Hungria, Andrew Spencer, Antonio Palumbo, Thorsten Graef, Joseph E Eid, Jennifer Houp, Linda Sun, Scott Vuocolo & Kenneth C Anderson. (2013) Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. The Lancet Oncology 14:11, pages 1129-1140.
Crossref
Noopur Raje & Sundar JagannathMaurizio ZangariTamara BernoFenghuang Zhan. 2013. Current & Emerging Therapeutics for Multiple Myeloma. Current & Emerging Therapeutics for Multiple Myeloma 68 81 .
Jiro Kikuchi, Satoshi Yamada, Daisuke Koyama, Taeko Wada, Masaharu Nobuyoshi, Tohru Izumi, Miyuki Akutsu, Yasuhiko Kano & Yusuke Furukawa. (2013) The Novel Orally Active Proteasome Inhibitor K-7174 Exerts Anti-myeloma Activity in Vitro and in Vivo by Down-regulating the Expression of Class I Histone Deacetylases. Journal of Biological Chemistry 288:35, pages 25593-25602.
Crossref
J Moreaux, T Reme, W Leonard, J-L Veyrune, G Requirand, H Goldschmidt, D Hose & B Klein. (2013) Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors. British Journal of Cancer 109:3, pages 676-685.
Crossref
Jonathan L. Kaufman, Claire Fabre, Sagar Lonial & Paul G. Richardson. (2013) Histone Deacetylase Inhibitors in Multiple Myeloma: Rationale and Evidence for Their Use in Combination Therapy. Clinical Lymphoma Myeloma and Leukemia 13:4, pages 370-376.
Crossref
Paul G. Richardson, Constantine S. Mitsiades, Jacob P. Laubach, Roman Hajek, Ivan Spicka, Meletios A. Dimopoulos, Philippe Moreau, David S. Siegel, Sundar Jagannath & Kenneth C. Anderson. (2013) Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leukemia Research 37:7, pages 829-837.
Crossref
Bo Cai, Hui Lyu, Jingcao Huang, Shuiliang Wang, Choon-Kee Lee, Chunji Gao & Bolin Liu. (2013) Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response. Cancer Letters 335:2, pages 343-350.
Crossref
Dominik Dytfeld. (2013) Translational research w szpiczaku plazmocytowym polsk? szans? na przyspieszenie?. Acta Haematologica Polonica 44:3, pages 196-199.
Crossref
Alexandra MR Marsh, Ruth Narramore, Keith Chapple, Alan J Lobo, Jonathan RL Wild & Bernard M Corfe. (2013) Histone deacetylase inhibitors: recent outcomes from clinical trials and the implications for oncology treatment approaches. Clinical Investigation 3:6, pages 571-594.
Crossref
Song Xu, Kim De Veirman, Holly Evans, Gaia Cecilia Santini, Isabelle Vande Broek, Xavier Leleu, Ann De Becker, Ben Van Camp, Peter Croucher, Karin Vanderkerken & Ivan Van Riet. (2013) Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo. Acta Pharmacologica Sinica 34:5, pages 699-709.
Crossref
Ken Maes, Eline Menu, Els Van Valckenborgh, Ivan Van Riet, Karin Vanderkerken & Elke De Bruyne. (2013) Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma. Cancers 5:4, pages 430-461.
Crossref
Teru Hideshima & Kenneth C. Anderson. (2013) Histone deacetylase inhibitors in the treatment for multiple myeloma. International Journal of Hematology 97:3, pages 324-332.
Crossref
Nathan G. Dolloff & Giampaolo Talamo. 2013. Impact of Genetic Targets on Cancer Therapy. Impact of Genetic Targets on Cancer Therapy 197 221 .
Angela Nebbioso, Vincenzo Carafa, Rosaria Benedetti & Lucia Altucci. (2012) Trials with ‘epigenetic’ drugs: An update. Molecular Oncology 6:6, pages 657-682.
Crossref
Maria New, Heidi Olzscha & Nicholas B. La Thangue. (2012) HDAC inhibitor-based therapies: Can we interpret the code?. Molecular Oncology 6:6, pages 637-656.
Crossref
Donna M. Weber, Thorsten Graef, Mohamad Hussein, Ronald M. Sobecks, Gary J. Schiller, Lisa Lupinacci, James S. Hardwick & Sundar Jagannath. (2012) Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 12:5, pages 319-324.
Crossref
Bastian Scholz & Rolf Marschalek. (2012) Epigenetics and blood disorders. British Journal of Haematology 158:3, pages 307-322.
Crossref
Carmela Dell'Aversana, Ilaria Lepore & Lucia Altucci. (2012) HDAC modulation and cell death in the clinic. Experimental Cell Research 318:11, pages 1229-1244.
Crossref
Takuya Kitamura, Kevin Connolly, Lynnsie Ruffino, Tetsuo Ajiki, Aline Lueckgen, John DiGiovanni & Kaoru Kiguchi. (2012) The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice. Journal of Hepatology 57:1, pages 84-91.
Crossref
Jasmine Zain. (2012) Role of Histone Deacetylase Inhibitors in the Treatment of Lymphomas and Multiple Myeloma. Hematology/Oncology Clinics of North America 26:3, pages 671-704.
Crossref
Philipp Baumann, Carmen Junghanns, Sonja Mandl‐Weber, Stefan Strobl, Fuat Oduncu & Ralf Schmidmaier. (2011) The pan‐histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells. British Journal of Haematology 156:5, pages 633-642.
Crossref
M. Pia Morelli, John J. Tentler, Gillian N. Kulikowski, Aik-Choon Tan, Erica L. Bradshaw-Pierce, Todd M. Pitts, Amy M. Brown, Sujatha Nallapareddy, John J. Arcaroli, Natalie J. Serkova, Manuel Hidalgo, Fortunato Ciardiello & S. Gail Eckhardt. (2012) Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models. Clinical Cancer Research 18:4, pages 1051-1062.
Crossref
Patricia Balsas, Patricia Galán-Malo, Isabel Marzo & Javier Naval. (2012) Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy. Leukemia Research 36:2, pages 212-218.
Crossref
Edvan de Queiroz Crusoe, Patricia Maiso, Diego Fernandez-Lazaro, Laura San-Segundo, Mercedes Garayoa, Antonio Garcia-Gomez, Norma C. Gutierrez, Manuel Delgado, Enrique Colado, Jesus Martin-Sanchez, Francis Y. Lee & Enrique M. Ocio. (2011) Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma. Annals of Hematology 91:2, pages 257-269.
Crossref
Jin LeeColin Mcguire. (2012) Clinical Efficacy of Vorinostat in a Patient with Leiomyosarcoma. Clinical Medicine Insights: Oncology 6, pages CMO.S7194.
Crossref
Ju-Hee Lee, Megan L. Choy & Paul A. Marks. 2012. Histone Deacetylase Inhibitors as Cancer Therapeutics. Histone Deacetylase Inhibitors as Cancer Therapeutics 39 86 .
Hakan Kaya, Benjamin Peressini, Irfan Jawed, Danko Martincic, Ameer L. Elaimy, Wayne T. Lamoreaux, Robert K. Fairbanks, Kevin A. Weeks & Christopher M. Lee. (2011) Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients. International Journal of Hematology 95:1, pages 64-70.
Crossref
Simon J. HarrisonHang QuachEmma LinkJohn F. SeymourDavid S. RitchieSam RuellJoanne DeanHenry JanuszewiczRicky Johnstone, Paul NeesonMichael DickinsonJean Nichols & H. Miles Prince. (2011) A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood 118:24, pages 6274-6283.
Crossref
Teru Hideshima, Paul G. Richardson & Kenneth C. Anderson. (2011) Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma. Molecular Cancer Therapeutics 10:11, pages 2034-2042.
Crossref
Teru Hideshima & Kenneth C. Anderson. (2011) Novel therapies in MM: from the aspect of preclinical studies. International Journal of Hematology 94:4, pages 344-354.
Crossref
Mark Andrew Dickson, Dana E. Rathkopf, Richard D. Carvajal, Steven Grant, John D. Roberts, Joel M. Reid, Matthew M. Ames, Renee M. McGovern, Robert A. Lefkowitz, Mithat Gonen, Lauren M. Cane, Heather J. Dials & Gary K. Schwartz. (2010) A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. Investigational New Drugs 29:5, pages 1004-1012.
Crossref
Li-Yuan Bai, Hany A. Omar, Chang-Fang Chiu, Zeng-Pang Chi, Jing-Lan Hu & Jing-Ru Weng. (2010) Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells. Cancer Chemotherapy and Pharmacology 68:2, pages 489-496.
Crossref
Shuhong Zhang, Attaya Suvannasankha, Colin D. Crean, Valerie L. White, Ching‐Shih Chen & Sherif S. Farag. (2010) The novel histone deacetylase inhibitor, AR‐42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells. International Journal of Cancer 129:1, pages 204-213.
Crossref
Niels W.C.J. van de Donk, Henk M. Lokhorst, Meletios Dimopoulos, Michele Cavo, Gareth Morgan, Hermann Einsele, Martin Kropff, Steve Schey, Hervé Avet-Loiseau, Heinz Ludwig, Hartmut Goldschmidt, Pieter Sonneveld, Hans E. Johnsen, Joan Bladé, Jesús F. San-Miguel & Antonio Palumbo. (2011) Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treatment Reviews 37:4, pages 266-283.
Crossref
V Cheriyath, M A Kuhns, M E Kalaycio & E C Borden. (2011) Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma. British Journal of Cancer 104:6, pages 957-967.
Crossref
Ruben Niesvizky, Scott Ely, Tomer Mark, Sangeeta Aggarwal, Janice L Gabrilove, John J. Wright, Selina Chen‐Kiang & Joseph A Sparano. (2010) Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 117:2, pages 336-342.
Crossref
Scott Thomas, Ashleigh Miller, Kenneth T. Thurn & Pamela Munster. 2011. Handbook of Epigenetics. Handbook of Epigenetics 597 615 .
Kevin D. Boyd, Faith E. Davies & Gareth J. Morgan. 2011. Multiple Myeloma. Multiple Myeloma 151 187 .
Thomas Moehler & Hartmut Goldschmidt. 2011. Multiple Myeloma. Multiple Myeloma 239 271 .
Nina ShahSagar Lonial. (2010) Evidence-Based Mini-Review: Treatment Options for Patients with Relapsed/Refractory Myeloma Previously Treated with Novel Agents and High-Dose Chemotherapy and Autologous Stem-Cell Transplantation. Hematology 2010:1, pages 310-313.
Crossref
Enrique M. Ocio & Jesús F. San Miguel. (2010) The DAC system and associations with multiple myeloma. Investigational New Drugs 28:S1, pages 28-35.
Crossref
Asher A. Chanan-Khan, Ivan Borrello, Kelvin P. Lee & Donna E. Reece. (2010) Development of target-specific treatments in multiple myeloma. British Journal of Haematology 151:1, pages 3-15.
Crossref
Sundar Jagannath, Meletios A. Dimopoulos & Sagar Lonial. (2010) Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma. Leukemia Research 34:9, pages 1111-1118.
Crossref
Francesco Paolo Tambaro, Carmela Dell’Aversana, Vincenzo Carafa, Angela Nebbioso, Branka Radic, Felicetto Ferrara & Lucia Altucci. (2010) Histone deacetylase inhibitors: clinical implications for hematological malignancies. Clinical Epigenetics 1:1-2, pages 25-44.
Crossref
Srividya Subramanian, Susan E. Bates, John J. Wright, Igor Espinoza-Delgado & Richard L. Piekarz. (2010) Clinical Toxicities of Histone Deacetylase Inhibitors. Pharmaceuticals 3:9, pages 2751-2767.
Crossref
Ciro Mercurio, Saverio Minucci & Pier Giuseppe Pelicci. (2010) Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacological Research 62:1, pages 18-34.
Crossref
Tiffany Richards & Donna Weber. (2010) Advances in treatment for relapses and refractory multiple myeloma. Medical Oncology 27:S1, pages 25-42.
Crossref
Minakshi Nihal, Craig T. Roelke & Gary S. Wood. (2010) Anti-Melanoma Effects of Vorinostat in Combination with Polyphenolic Antioxidant (−)-Epigallocatechin-3-Gallate (EGCG). Pharmaceutical Research 27:6, pages 1103-1114.
Crossref
Shannon A. Kavanaugh, Lisa A. White & Jill M. Kolesar. (2010) Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. American Journal of Health-System Pharmacy 67:10, pages 793-797.
Crossref
Thorsten Stühmer, Janine Arts, Manik Chatterjee, Johanna Borawski, André Wolff, Peter King, Hermann Einsele, Eugen Leo & Ralf C. Bargou. (2010) Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585. British Journal of Haematology 149:4, pages 529-536.
Crossref
Sonja Mandl-Weber, Felix G. Meinel, Rüdiger Jankowsky, Fuat Oduncu, Ralf Schmidmaier & Philipp Baumann. (2010) The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. British Journal of Haematology 149:4, pages 518-528.
Crossref
Amitabha Mazumder, David H. Vesole & Sundar Jagannath. (2010) Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: A Case Series Illustrating Utility in Clinical Practice. Clinical Lymphoma Myeloma and Leukemia 10:2, pages 149-151.
Crossref
Anuj MahindraDiana Cirstea & Noopur Raje. (2010) Novel therapeutic targets for multiple myeloma. Future Oncology 6:3, pages 407-418.
Crossref
Emma M. Smith, Kevin Boyd & Faith E. Davies. (2010) The potential role of epigenetic therapy in multiple myeloma. British Journal of Haematology 148:5, pages 702-713.
Crossref
Alessandro Rambaldi. (2010) Therapy of myelofibrosis (excluding JAK2 inhibitors). International Journal of Hematology 91:2, pages 180-188.
Crossref
Sundar Jagannath, Robert A. Kyle, Antonio Palumbo, David S. Siegel, Sonia Cunningham & James Berenson. (2010) The Current Status and Future of Multiple Myeloma in the Clinic. Clinical Lymphoma Myeloma and Leukemia 10:1, pages 28-43.
Crossref
Sundar Jagannath, Robert A. Kyle, Antonio Palumbo, David S. Siegel, Sonia Cunningham & James Berenson. (2010) The Current Status and Future of Multiple Myeloma in the Clinic. Clinical Lymphoma, Myeloma & Leukemia 10:1, pages E1-E16.
Crossref
Monica Galli, Silvia Salmoiraghi, Joseé Golay, Antonella Gozzini, Claudia Crippa, Norbert Pescosta & Alessandro Rambaldi. (2009) A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Annals of Hematology 89:2, pages 185-190.
Crossref
Colin McGuireJin Lee. (2017) Brief Review of Vorinostat. Clinical Medicine Insights: Therapeutics 2, pages CMT.S1102.
Crossref
Kateřina Kuželová, Michaela Pluskalová, Barbora Brodská, Petra Otevřelová, Klára Elknerová, Dana Grebeňová & Zbyněk Hrkal. (2010) Suberoylanilide hydroxamic acid (SAHA) at subtoxic concentrations increases the adhesivity of human leukemic cells to fibronectin. Journal of Cellular Biochemistry 109:1, pages 184-195.
Crossref
Madeleine Duvic, Elise A. Olsen, Debra Breneman, Theresa R. Pacheco, Sareeta Parker, Eric C. Vonderheid, Rachel Abuav, Justin L. Ricker, Syed Rizvi, Cong Chen, Kathleen Boileau, Alexandra Gunchenko, Cesar Sanz-Rodriguez & Larisa J. Geskin. (2009) Evaluation of the Long-Term Tolerability and Clinical Benefit of Vorinostat in Patients With Advanced Cutaneous T-Cell Lymphoma. Clinical Lymphoma and Myeloma 9:6, pages 412-416.
Crossref
David Siegel, Mohamad Hussein, Chandra Belani, Francisco Robert, Evanthia Galanis, Victoria M Richon, José Garcia-Vargas, Cesar Sanz-Rodriguez & Syed Rizvi. (2009) Vorinostat in solid and hematologic malignancies. Journal of Hematology & Oncology 2:1.
Crossref
Shundong Cang, Yuehua Ma & Delong Liu. (2009) New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. Journal of Hematology & Oncology 2:1.
Crossref
Nassera Aouali, Valérie Palissot, Victoria El‐Khoury, Etienne Moussay, Bassam Janji, Sandrine Pierson, Nicolaas H. C. Brons, Laurent Kellner, Manon Bosseler, Kris Van Moer & Guy Berchem. (2009) Peroxisome proliferator‐activated receptor γ agonists potentiate the cytotoxic effect of valproic acid in multiple myeloma cells. British Journal of Haematology 147:5, pages 662-671.
Crossref
Deborah Bradley, Dana Rathkopf, Rodney Dunn, Walter M. Stadler, Glenn Liu, David C. Smith, Roberto Pili, James Zwiebel, Howard Scher & Maha Hussain. (2009) Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862). Cancer 115:23, pages 5541-5549.
Crossref
Diana Cirstea, Sonia Vallet & Noopur Raje. (2009) Future Novel Single Agent and Combination Therapies. The Cancer Journal 15:6, pages 511-518.
Crossref
Jacob K Kettle, Karen L Finkbiner, Susan E Klenke, Ronald D Baker, Dave W Henry & Casey B Williams. (2009) Initial therapy in multiple myeloma: investigating the new treatment paradigm. Journal of Oncology Pharmacy Practice 15:3, pages 131-141.
Crossref
Yutaka Fujiwara, Noboru Yamamoto, Yasuhide Yamada, Kazuhiko Yamada, Tetsuya Otsuki, Shinichi Kanazu, Takashi Iwasa, James S. Hardwick & Tomohide Tamura. (2009) Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. Cancer Science 100:9, pages 1728-1734.
Crossref
Tatsuhito Nagumo, Sayaka Takaoka, Sayaka Yoshiba, Masaru Ohashi, Tatsuo Shirota, Masashi Hatori, Tomohide Isobe, Tetsuhiko Tachikawa & Satoru Shintani. (2009) Antitumor activity of suberoylanilide hydroxamic acid against human oral squamous cell carcinoma cell lines in vitro and in vivo. Oral Oncology 45:9, pages 766-770.
Crossref
Ashraf Badros, Angelika M. Burger, Sunita Philip, Ruben Niesvizky, Sarah S. Kolla, Olga Goloubeva, Carolynn Harris, James Zwiebel, John J. Wright, Igor Espinoza-Delgado, Maria R. Baer, Julianne L. Holleran, Merrill J. Egorin & Steven Grant. (2009) Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma. Clinical Cancer Research 15:16, pages 5250-5257.
Crossref
L. Stimson, V. Wood, O. Khan, S. Fotheringham & N.B. La Thangue. (2009) HDAC inhibitor-based therapies and haematological malignancy. Annals of Oncology 20:8, pages 1293-1302.
Crossref
Nina Saban & Maro Bujak. (2009) Hydroxyurea and hydroxamic acid derivatives as antitumor drugs. Cancer Chemotherapy and Pharmacology 64:2, pages 213-221.
Crossref
H. Miles Prince, Mark J. Bishton & Simon J. Harrison. (2009) Clinical Studies of Histone Deacetylase Inhibitors. Clinical Cancer Research 15:12, pages 3958-3969.
Crossref
Sonia Cunningham, Sabeeha Muneer, Sundar Jagannath, Sagar Lonial, Stefan Faderl & Stephan Stilgenbauer. (2009) The 50th Annual Meeting of the American Society of Hematology. Clinical Lymphoma and Myeloma 9:3, pages 197-205.
Crossref
Constantine S. Mitsiades, Teru Hideshima, Dharminder Chauhan, Douglas W. McMillin, Steffen Klippel, Jacob P. Laubach, Nikhil C. Munshi, Kenneth C. Anderson & Paul G. Richardson. (2009) Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and Bortezomib. Seminars in Hematology 46:2, pages 166-175.
Crossref
Barbora Brodska, Petra Otevrelova & Ivan Kalousek. (2009) Variations in c‐Myc and p21WAF1 expression protect normal peripheral blood lymphocytes against BimEL‐mediated cell death. Cell Biochemistry and Function 27:3, pages 167-175.
Crossref
Efstathios Kastritis, Andreas Charidimou, Andreas Varkaris & Meletios A. Dimopoulos. (2009) Targeted therapies in multiple myeloma. Targeted Oncology 4:1, pages 23-36.
Crossref
A. Keith Stewart. (2009) Novel therapies for relapsed myeloma. Hematology 2009:1, pages 578-586.
Crossref
Min-Jung Lee, Yeong Sang Kim, Shivaani Kummar, Giuseppe Giaccone & Jane B Trepel. (2008) Histone deacetylase inhibitors in cancer therapy. Current Opinion in Oncology 20:6, pages 639-649.
Crossref
Thi Lien-Anh NguyênHesham AbdelbaryMeztli ArguelloCaroline BreitbachSimon Leveille, Jean-Simon DialloAmber Yasmeen, Tarek A. BismarDavid KirnTheresa FallsValerie E. SnoultenBarbara C. VanderhydenJoel WerierHarold AtkinsMarkus J. V. Vähä-KoskelaDavid F. Stojdl, John C. BellJohn Hiscott. (2008) Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proceedings of the National Academy of Sciences 105:39, pages 14981-14986.
Crossref
James R Berenson & Ori Yellin. (2008) New drugs in multiple myeloma. Current Opinion in Supportive and Palliative Care 2:3, pages 204-210.
Crossref
Alessandro Rambaldi, Tiziano Barbui & Giovanni Barosi. (2008) From Palliation to Epigenetic Therapy in Myelofibrosis. Hematology 2008:1, pages 83-91.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.